CurePSP Forms Subsidiary to Promote Clinical Trials

News Releases
Written By

CurePSP has formed the new Patient Engagement Program (PEP) to help speed recruitment of eligible participants for industry-sponsored clinical trials, with the goal of finding treatments for degenerative brain diseases. Agreements have been reached with Bristol-Myers Squibb and AbbVie.Read the press release.

Previous

C₂N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy
Next

C₂N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy